Gao-Jun Teng, MD, contextualizes efficacy data with TACE plus camrelizumab and rivoceranib in HCC from the phase 2 CARES-005 trial.
Gao-Jun Teng, MD
Advertisement
Articles by Gao-Jun Teng, MD
Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC
Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.
Advertisement
Latest Updated Articles
Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCCPublished: January 25th 2025 | Updated:
Dr Teng on the Implications of Data From the CARES-005 Trial of TACE Plus Camrelizumab/Rivoceranib in HCCPublished: March 28th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5